🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

529 results for “Teva” Clear

  1. TEV-56248

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule active

    2 trials

  2. TV-1106

    Teva Pharma GmbH

    Growth Hormone-Deficiency

    phase 3 small molecule terminated

    4 trials

  3. TV-44749

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    3 trials

  4. TV-46000

    Teva Pharma GmbH

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  5. TV-46763

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

  6. TVB-009

    Teva Pharma GmbH

    Osteoporosis, Postmenopausal

    phase 3 other completed

    1 trial

  7. Tacrolimus BID

    Teva Pharma GmbH

    Medication Adherence

    phase 3 small molecule active

    1 trial

  8. Tapinarof Cream 1%

    Teva Pharma GmbH

    Plaque Type Psorisis

    phase 3 small molecule completed

    1 trial

  9. Tbo-filgrastim

    Teva Pharma GmbH

    Healthy Participants

    phase 3 small molecule terminated

    1 trial

  10. Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 small molecule active

    1 trial

  11. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  12. Trifarotene 0.005 % Topical Cream

    Teva Pharma GmbH

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  13. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  14. albuterol aerosol by HFA MDI

    Teva Pharma GmbH

    Exercise-induced Bronchospasm

    phase 3 small molecule completed

    1 trial

  15. beclomethasone dipropionate (QVAR)

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  16. bendamustine

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    2 trials

  17. custirsen sodium

    Teva Pharma GmbH

    Castrate-Resistant Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  18. cyclobenzaprine hydrochloride

    Teva Pharma GmbH

    Chronic Migraine

    phase 3 small molecule terminated

    1 trial

  19. levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

    Teva Pharma GmbH

    Dysmenorrhea

    phase 3 small molecule completed

    2 trials

  20. lipegfilgrastim

    Teva Pharma GmbH

    Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

    phase 3 small molecule completed

    1 trial

  21. non-pegylated liposomal doxorubicin

    Teva Pharma GmbH

    Tubular Breast Cancer Stage II

    phase 3 small molecule completed

    1 trial

  22. pagoclone

    Teva Pharma GmbH

    Stuttering

    phase 3 small molecule completed

    1 trial

  23. rasagiline

    Teva Pharma GmbH

    Restless Legs Syndrome

    phase 3 small molecule terminated

    1 trial

  24. reslizumab

    Teva Pharma GmbH

    Eosinophils, Asthma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources